rivastigmine

出典: meddic

リバスチグミン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/09/18 21:17:28」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease.
  • Weng PH1, Chen JH2, Chen TF3, Sun Y4, Wen LL5, Yip PK6, Chu YM7, Chen YC8.Author information 1Department of Family Medicine, Taiwan Adventist Hospital, Taipei, Taiwan ; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.2Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan ; Department of Geriatrics and Gerontology, National Taiwan University Hospital, Taipei, Taiwan.3Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.4Department of Neurology, En Chu Kong Hospital, Taipei, Taiwan.5Department of Laboratory Medicine, En Chu Kong Hospital, Taipei, Taiwan.6Center of Neurological Medicine, Cardinal Tien Hospital, Taipei, Taiwan ; School of Medicine, Fu-Jen Catholic University, Taipei, Taiwan.7Department of Laboratory Medicine, Cardinal Tien Hospital, Taipei, Taiwan.8Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan ; Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan ; Research Center for Genes, Environment and Human Health, College of Public Health, National Taiwan University, Taipei, Taiwan.AbstractBACKGROUND: CHRNA7 encodes the α7 nicotinic acetylcholine receptor subunit, which is important to Alzheimer's disease (AD) pathogenesis and cholinergic neurotransmission. Previously, CHRNA7 polymorphisms have not been related to cholinesterase inhibitors (ChEI) response.
  • PloS one.PLoS One.2013 Dec 31;8(12):e84059. doi: 10.1371/journal.pone.0084059.
  • BACKGROUND: CHRNA7 encodes the α7 nicotinic acetylcholine receptor subunit, which is important to Alzheimer's disease (AD) pathogenesis and cholinergic neurotransmission. Previously, CHRNA7 polymorphisms have not been related to cholinesterase inhibitors (ChEI) response.METHODS: Mild to moderate AD
  • PMID 24391883
  • Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysis.
  • Ferris S, Karantzoulis S, Somogyi M, Meng X.AbstractINTRODUCTION: The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as assessed by SIB factor scores, in patients with moderately severe-to-severe Alzheimer's disease (AD).
  • Alzheimer's research & therapy.Alzheimers Res Ther.2013 Dec 18;5(6):63. [Epub ahead of print]
  • INTRODUCTION: The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as assessed by SIB factor scores, in patients with moderately severe-to-severe A
  • PMID 24351447
  • Pharmacological treatment for memory disorder in multiple sclerosis.
  • He D, Zhang Y, Dong S, Wang D, Gao X, Zhou H.Author information Department of Neurology, Affiliated Hospital of Guiyang Medical College, No. 28, Gui Yi Street, Guiyang, Guizhou Province, China, 550004.AbstractBACKGROUND: This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10).Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system (CNS) and can cause both neurological and neuropsychological disability. Both demyelination and axonal and neuronal loss are believed to contribute to MS-related cognitive impairment. Memory disorder is one of the most frequent cognitive dysfunctions and presents a considerable burden to people with MS and to society due to the negative impact on function. A number of pharmacological agents have been evaluated in many existing randomised controlled trials for their efficacy on memory disorder in people with MS but the results were not consistent.
  • The Cochrane database of systematic reviews.Cochrane Database Syst Rev.2013 Dec 17;12:CD008876. doi: 10.1002/14651858.CD008876.pub3.
  • BACKGROUND: This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10).Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the centr
  • PMID 24343792

和文文献

  • 抗認知症薬の最近の動向 (特集 認知症 最前線)
  • 中村 祐
  • Monthly book medical rehabilitation (127), 65-69, 2011-01
  • NAID 40018281974
  • リバスチグミン--経皮吸収型製剤への期待 (特集 アルツハイマー病治療薬の現状と期待される治療薬)
  • 中村 祐
  • 老年精神医学雑誌 21(12), 1336-1347, 2010-12
  • NAID 40017427216

関連リンク

Rivastigmine (sold under the trade name Exelon) is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and dementia due to Parkinson's disease. The drug can be ...
Before taking rivastigmine, tell your doctor and pharmacist if you have ever had an allergic reaction to rivastigmine after taking the capsule or oral solution or using the skin patch, any other medications, or any of the ...

関連画像

Rivastigmine Generic | Buy Rivastigmine  علاج الزهايمر -rivastigmineRivastigmine Sandoz | Irish Medical TimesRivastigmine 4.5mg (generic equivalent to Rivastigmine hydrogen tartrate is Order Rivastigmine 6mg (generic equivalent


★リンクテーブル★
リンク元リバスチグミン
拡張検索rivastigmine tartrate

リバスチグミン」

  [★]

rivastigmine
酒石酸リバスチグミン rivastigmine tartrate
イクセロンリバスタッチ
抗認知症薬その他の中枢神経系用薬
  • アセチルコリンエステラーゼとブチリルコリンエステラーゼ BuChEを両方共に阻害する。
  • BuChEは海馬に多く存在。AChEは神経に多く存在、BuChEは神経細胞やグリア細胞、血管内皮細胞にも存在。(週刊 医学会新聞 2011/5/23)
  • 副作用(消化器症状)が多いので、パッチ剤のみ存在。


rivastigmine tartrate」

  [★] 酒石酸リバスチグミン




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡